Health care solutions company AXIM Biotechnologies Inc AXIM plans to use a new patent to formulate a chewing gum with cannabinoids and nicotine that aids tobacco smokers in overcoming their addiction.
The company, an international firm targeting oncological and cannabinoid research, confirmed Wednesday that i received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the product.
The chewing gum will also be formulated using the company's well-known proprietary chewing gum mechanism.
"AXIM looks to provide a unique and effective solution to the millions of smokers who want to quit smoking," AXIM Biotech CEO John W. Huemoeller II told Benzinga. "With over one billion tobacco smokers worldwide, we have a great opportunity to make a big difference in the $21.8 billion smoking cessation market."
With this new patent issuance, AXIM now holds nine patents, one newly issued allowance and has 13 patents pending. Of these, AXIM is best known for its patent on chewing gum as a delivery mechanism for all cannabinoids, including CBD, THC and the increasingly popular CBG. The company already makes and sells several nutraceutical products including Wellness Gum, Wellness Gum PM, Hole-In-One Gum and Workout Gum.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!